Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCOR: Calcitriol vs Paricalcitol in CKD
NCT00752102Phase 4Completed
- Sponsor
- Joslin Diabetes Center
- Start
- Sep 2008
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Joslin Diabetes Center. Primary endpoint: Coronary Artery Calcification Score Progression at 48 weeks. Started Sep 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00752102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752102.